Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Derek Ngai

Pediatric Gastroenterology Dallas, TX Medical Doctor

NPI 1700231859 CMS profile 7226320

1935 Medical District Dr, Dallas, TX 75235

Open in the dashboard

General payments

$2,735

119 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Derek Ngai of Dallas, TX is reported in the CMS Open Payments database as having received $2,735 across 119 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Pediatric Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $449 20
2024 General $452 22
2023 General $701 34
2022 General $198 9
2021 General $366 15
2020 General $330 13
2019 General $239 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Derek Ngai
  • Pediatric Gastroenterology median
  • Middle half of Pediatric Gastroenterology
  • National median

In program year 2025, general payments to Derek Ngai were reported at $449. Among 1,132 Pediatric Gastroenterology profiles paid that year, the median was $194 and the middle half received between $81 and $540.

Show as a table
Year Derek Ngai Pediatric Gastroenterology median Middle half National median
2019 $239 $131 $41–$311 $163
2020 $330 $79 $23–$223 $114
2021 $366 $104 $32–$321 $132
2022 $198 $125 $37–$331 $149
2023 $701 $169 $55–$440 $160
2024 $452 $196 $73–$563 $164
2025 $449 $194 $81–$540 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $579 27 payments
  2. AbbVie, Inc. $555 22 payments
  3. QOL Medical, LLC $355 11 payments
  4. Regeneron Healthcare Solutions, Inc. $323 16 payments
  5. Mirum Pharmaceuticals, Inc. $192 10 payments
  6. Alcresta Therapeutics, Inc. $149 6 payments
  7. Janssen Biotech, Inc. $124 7 payments
  8. Amgen Inc. $77 3 payments
  9. IntraBio Inc $69 3 payments
  10. Genzyme Corporation $62 2 payments
  11. Other $251 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,713 118 payments
  2. Education $22 1 payment
Products named General payments · program years 2019–2025
  1. HUMIRA $505 20 payments
  2. GATTEX $460 21 payments
  3. Sucraid Therapy For Csid $268 7 payments
  4. DUPIXENT $255 13 payments
  5. Livmarli $170 9 payments
  6. RELIZORB $149 6 payments
  7. STELARA $124 7 payments
  8. Sucraid Therapy For Csid $87 4 payments
  9. EOHILIA $81 4 payments
  10. AQNEURSA $69 3 payments
  11. Other $574 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Gastroenterology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record